Literature DB >> 15834033

Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.

Y Nemoto1, S Kuwabara, S Misawa, N Kawaguchi, T Hattori, M Takamori, A Vincent.   

Abstract

OBJECTIVES: To compare the clinical and electrophysiological features of myasthenia gravis (MG) patients with (seropositive) or without (seronegative) antibodies to acetylcholine receptor. To investigate whether antibodies to muscle specific kinase (MuSK) and ryanodine receptor (RyR) are associated with particular features.
METHODS: Clinical profiles and single fibre electromyography (SFEMG) in the extensor digitorum communis (EDC) were reviewed in consecutive 57 seropositive and 13 seronegative patients. Antibodies to MuSK and RyR were measured by immunoassays.
RESULTS: Of the 13 seronegative patients, four (31%) were positive for MuSK antibodies and seven (54%) were positive for RyR antibodies, including all four MuSK positive patients. Clinical features were similar at presentation for seropositive and seronegative patients, but MuSK positive patients frequently developed myasthenic crises. Despite the similar clinical severities at the time of examination, the proportion with positive jitter (93% of seropositive patients, 50% of MuSK positive patients, and 44% of MuSK negative patients) and the extent of jitter (mean consecutive difference: 76 micros in seropositive patients, 36 micros in MuSK positive patients, and 30 micros in MuSK negative patients) were less in seronegative MG patients compared with seropositive MG patients.
CONCLUSIONS: Seronegative MG is heterogeneous with respect to the presence of antibodies to MuSK. Impairment of neuromuscular synaptic transmission in EDC is less marked in seronegative than seropositive MG despite the similar clinical severity. This discrepancy may partly reflect the distribution of affected muscles in seronegative patients, but it is possible that other factors, such as impaired excitation-contraction coupling resulting from RyR antibodies, contribute to the clinical phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834033      PMCID: PMC1739635          DOI: 10.1136/jnnp.2004.043125

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

Review 1.  The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction.

Authors:  Yohan Liyanage; Werner Hoch; David Beeson; Angela Vincent
Journal:  Muscle Nerve       Date:  2002-01       Impact factor: 3.217

2.  Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.

Authors:  A K Lefvert; K Bergström; G Matell; P O Osterman; R Pirskanen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

3.  Clinical electrophysiology in myasthenia gravis.

Authors:  E Stalberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

Review 4.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

5.  Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?

Authors:  C Buckley; J Newsom-Davis; N Willcox; A Vincent
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

Review 6.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

Authors:  Angela Vincent; John Bowen; John Newsom-Davis; John McConville
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

7.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

8.  Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies.

Authors:  K Iwasa; K Komai; M Takamori
Journal:  Muscle Nerve       Date:  1998-12       Impact factor: 3.217

9.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

Authors:  Amelia Evoli; Pietro A Tonali; Luca Padua; Mauro Lo Monaco; Flavia Scuderi; Anna P Batocchi; Mariapaola Marino; Emanuela Bartoccioni
Journal:  Brain       Date:  2003-06-23       Impact factor: 13.501

10.  Clinical aspects of MuSK antibody positive seronegative MG.

Authors:  D B Sanders; K El-Salem; J M Massey; J McConville; A Vincent
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

View more
  9 in total

1.  In response to "current approach to seronegative myasthenia" by Z. Argov.

Authors:  Michal Haran
Journal:  J Neurol       Date:  2010-11-18       Impact factor: 4.849

Review 2.  Current approach to seronegative myasthenia.

Authors:  Zohar Argov
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

Review 3.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

4.  Determination of the normative values of the masseter muscle by single-fiber electromyography in myasthenia gravis patients.

Authors:  Lei Shi; Heng-Fang Liu; Min Zhang; Ya-Pei Guo; Bo Song; Chang-Dong Song; Dan-Dan Song; Yu-Ming Xu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 5.  Treatment of Myasthenia Gravis in the Aged.

Authors:  Nuha M Alkhawajah; Joel Oger
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

6.  Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Authors:  Giovanna Cenacchi; Valentina Papa; Papa Valentina; Marina Fanin; Fanin Marina; Elena Pegoraro; Pegoraro Elena; Corrado Angelini; Angelini Corrado
Journal:  J Neurol       Date:  2010-11-19       Impact factor: 4.849

7.  A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis.

Authors:  Yu Cai; Lu Han; Desheng Zhu; Jing Peng; Jianping Li; Jie Ding; Jiaying Luo; Ronghua Hong; Kan Wang; Wenbin Wan; Chong Xie; Xiajun Zhou; Ying Zhang; Yong Hao; Yangtai Guan
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

Review 8.  Bedside and laboratory diagnostic testing in myasthenia.

Authors:  Katie Yoganathan; Alexander Stevenson; Awais Tahir; Ross Sadler; Aleksandar Radunovic; Naveed Malek
Journal:  J Neurol       Date:  2022-02-10       Impact factor: 6.682

9.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.